Pricing Log in Create free account
Saturday 17 October 2026 Export ACON’s income statement to Excel — free account

Aclarion, Inc.

ACON Healthcare Health Information Services

Aclarion, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75,700.00, up 65.6% from fiscal 2024. In the quarter to June 2026, revenue grew 30.6%, EPS grew 59.3% and free cash flow fell 41.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.85 0.10 −5.13%
Market cap
$5.6M
P/E
0.0×
Fwd P/E
−0.8×
Dividend yield
—
F-score
5/9
Altman Z
−4.92
Beneish M
−7.47
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.18
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy 1 — — — — — 4 — — 6 — —
Sell — — — — — — — — — — — —
Insider Ownership 17.15%

Capital & Financial Ratios $m

Market Cap 5.63
Revenue 0.08
Net Income (9.20)
Free Cash Flow (8.26)
Net Debt (16.31)
Current Ratio 16.20 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 0.00
Fwd P/E (0.79) (negative: loss-making)
P/S ratio 54.42 (above 10: high)
P/B ratio 0.27
Past 5Y EPS Growth —
This Y EPS Growth 65.27% (at or above 15%: strong)
Next Y EPS Growth 35.44% (at or above 15%: strong)
Next Y revenue growth 44.65% (at or above 10%: strong)
Next 5Y EPS Growth 50.26% (at or above 15%: strong)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is −137×, against a ten-year median of −3.0×; over the ten years it ranged from −240× in 2025 to 29,493,802× in 2022.
P/S against its own 10 years 46.01%
10-year low 10-year high
P/B against its own 10 years 18.79%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 1 0 12 16
Receivables 0 0 0 0
Inventory — — — —
Other — 0 0 0
1 1 12 17
2023 2024 2025 Q'26
Payables 1 1 0 1
ST’ Debt — — — —
Other 0 0 0 0
3 1 1 1

Compound Annual Growth %

10y 5y 3y
Sales — 9.22% 7.82%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 0.00% 79.32%

Revenue $m

Mar Jun Sep Dec Year
’26 0 0 — — —
’25 0 0 0 0 0
’24 0 0 0 0 0
’23 0 0 0 0 0
’22 0 0 0 0 0
’21 0 0 0 0 0
’20 — — 0 0 0
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (3) (2) (1) (2) (7)
’24 (2) (1) (1) (1) (5)
’23 (1) (1) (1) (1) (4)
’22 0 (2) (1) (1) (5)
’21 0 0 (1) (1) (2)
’20 — — — (2) (2)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (3) (3) — — —
’25 (3) (2) (1) (2) (7)
’24 (2) (1) (1) (1) (6)
’23 (1) (1) (1) (1) (4)
’22 0 (2) (1) (1) (5)
’21 0 (1) (1) (1) (3)
’20 — — — (2) (2)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (1.34) (1.12) — — —
’25 (9.32) (2.75) (2.93) (2.01) (13.61)
’24 (3.96k) (1.35k) (1.35k) (757.02) (7.48k)
’23 (21.62k) (25.95k) (17.30k) (15.38k) (79.46k)
’22 (1.03) (0.45) (0.21) (166.88k) (166.88k)
’21 (0.57) (0.51) (3.26) (1.12) (5.47)
’20 — — — — (0.69)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low — — — — — — 54,993.60 26,194.32 904.50 4.32

Analyst estimates 2026–2028

Powerpack
High — — — — — — 586,116.00 342,986.41 61,053.75 3,500.42
People
People Employees — — — — — 6 7 6 6 11
Revenue/emp, $m — — — 0.00 0.00 0.01 0.01 0.01 0.01 0.01
Income, $m
Income, $m Revenue — — — 0 0 0 0 0 0 0
Gross margin, % — — — (576.58) (36.14) (14.76) (8.11) (0.40) (85.12) 8.98
EBT — — — (4) (5) (5) (7) (5) (7) (7)
EBT margin, % — — — (14,941.64) (9,517.86) (8,209.45) (11,702.98) (6,513.79) (15,301.75) (9,555.61)
Net income — 0 — (4) (5) (5) (7) (5) (7) (7)
Depreciation — — — 0 0 0 0 1 1 0
Per share, $
Per share, $ Revenue — — — 0.06 0.01 0.07 0.00 754.00 50.78 0.14
Earnings — — — (10.80) (0.69) (5.47) (140,171.20) (79,459.45) (7,480.00) (13.61)
Cash flow — — — (9.29) (0.27) (2.65) 0.00 (36,469.00) (5,857.33) (13.47)
Capex — — — 0.00 (0.03) (0.11) 0.00 (1,195.00) (357.67) (0.38)
Free cash flow — — — (9.29) (0.29) (2.76) 0.00 (37,664.00) (6,215.00) (13.85)
Book value — — — (3.79) (1.05) (6.33) 0.00 (7,280.00) 1,077.89 24.13
Shares, m — — — 0 7 1 0 0 0 1
Valuation, ×
Valuation, × P/E — — — 0.00 0.00 0.00 0.00 0.00 0.00 0.00
P/S — — — 6,200,318.40 6,200,318.40 6,200,318.40 0.00 39.68 25.65 32.33
P/B — — — 0.00 0.00 0.00 0.00 0.00 1.21 0.19
EV/Sales — — — 6,200,321.64 6,200,321.64 6,200,321.64 (20.46) 29.29 20.91 (123.47)
EV/FCF — — — (138,507.57) (138,507.57) (138,507.57) 0.24 (0.59) (0.17) 1.27
Cash, $m
Cash, $m Operating cash flow — — — (4) (2) (2) (5) (4) (5) (7)
Capex — — — 0 0 0 0 0 0 0
Free cash flow — — — (4) (2) (3) (5) (4) (6) (7)
Balance, $m
Balance, $m Working capital — — — (3) (8) (7) 1 (2) 0 12
Total debt — — — 1 0 2 0 — — —
Net debt — — — 0 0 0 (1) (1) 0 (12)
Shareholders’ equity — — — (2) (7) (6) 2 (1) 1 13
Returns, %
Returns, % ROA — — — (677.67) (403.12) (374.43) (311.57) (182.77) (307.75) (91.67)
ROIC — — — 0.00 0.00 0.00 (467.71) 0.00 (680.42) (554.92)
ROE — — — 0.00 124.90 59.81 141.13 (655.73) (5,826.19) (104.89)
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Aclarion, Inc. vs peers in Health Information Services (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
RNLXY Renalytix plc - Sponsored ADR $17.2M — (loss-making) — +13.73% (above 0%: growing) n/m +17.96% (above 0%: growing) 19.16% (783.91%) Compare
BFRG Bullfrog AI Holdings Inc. $9.9M — (loss-making) — +2,054.00% (above 0%: growing) n/m −5.67% (below 0%: shrinking) 49.63% (658.82%) Compare
ETAOF ETAO International Co., Ltd. $9.8M — (loss-making) — — n/m +37,595.70% (above 0%: growing) — 0.00% Compare
HCTI Healthcare Triangle, Inc. $7.4M 0.0× — (loss-making) +158.38% (above 0%: growing) n/m +67.48% (above 0%: growing) 22.48% (44.28%) Compare
MGRX Mangoceuticals, Inc. $7.1M — (loss-making) — −59.07% (below 0%: shrinking) n/m +79.27% (above 0%: growing) 64.24% (1,501.45%) Compare
HLTHQ Cue Health Inc. $6.9M — (loss-making) — (loss-making) −87.19% (below 0%: shrinking) n/m +50.55% (above 0%: growing) (90.14%) (792.13%) Compare
ZCMD Zhongchao Inc. $6.2M — (loss-making) — +20.44% (above 0%: growing) −550.00% (below 0%: shrinking) +191.85% (above 0%: growing) 41.67% 0.00% Compare
ACON Aclarion, Inc. $5.6M — (loss-making) — (loss-making) +30.57% (above 0%: growing) n/m −41.41% (below 0%: shrinking) 32.94% (11,506.75%)
VSEED VSee Health, Inc. $2.8M — (loss-making) — (loss-making) +48.02% (above 0%: growing) n/m −257.62% (below 0%: shrinking) 13.20% (172.69%) Compare
Median of peers $7.3M — — +20.44% — +59.02% 22.48% (415.75%)

All 51 Health Information Services stocks →

Aclarion, Inc. (ACON) key facts

  • Strength: Aclarion, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75,700.00, up 65.6% from fiscal 2024.
  • Aclarion, Inc. (ACON) is a Health Information Services company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, ACON traded at $1.85, a market capitalization of $5.6 million.
  • Return on equity was −104.9% and debt-to-equity 0.00.
  • Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −4.92 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Aclarion, Inc. (ACON) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/ACON · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com